Octave Bioscience Inc

MENLO PARK, CA · Founded 2014 · Medtech · Private

Blood test measuring 18 biomarkers to diagnose and monitor multiple sclerosis

Claim this profile

Follows are private to you and power your alerts

Updated · octavebio.com

Sector
Medtech
Headquarters
MENLO PARK, CA
Founded
2014
Latest Form D
$31.8M, Mar 2025
Total capital
$106M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$106M
5 Form D · last Mar 2025
19 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
18 pending · first 2023
Rank in peer group#45 of 160

Capital timeline

20172019202120232025FEDERAL ↑EQUITY ↓Cumulative $106M1st Form D$2.5M2nd Form D$32M4th Form D$32.5M5th Form D$31.8M
20172019202120232025FEDERAL ↑EQUITY ↓Cumulative $106M2nd Form D$32M4th Form D$32.5M

Latest events

  • Private capital raisedForm D · SEC · 5th filing$31.8M
  • Private capital raisedForm D · SEC · 4th filing$32.5M
  • Private capital raisedForm D · SEC · 3rd filing$7M
  • Private capital raisedForm D · SEC · 2nd filing$32M
  • Private capital raisedForm D · SEC · 1st filing$2.5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 160 peers

Line = median

Medtech · Instrument

  • Granted patents#45 · top 28%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • William HagstromResearcherDirectorLinked by 1 patent
  • A. Grant Heidrich IIIDirectorNamed in SEC Form D filings
  • Andrea JacksonDirectorNamed in SEC Form D filings
  • Brook ByersDirectorNamed in SEC Form D filings
  • Doug BiehnExecutive Officer, DirectorNamed in SEC Form D filings
  • George ScangosDirectorNamed in SEC Form D filings
Show all 12 people
  • Lucy CoassinDirectorNamed in SEC Form D filings
  • Marcel KonradExecutive OfficerNamed in SEC Form D filings
  • Mark WeeksExecutive OfficerNamed in SEC Form D filings
  • Melinda ThomasExecutive OfficerNamed in SEC Form D filings
  • Michael PelliniDirectorNamed in SEC Form D filings
  • Thomas HawesDirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 20
  • PendingBiomarkers for Predicting Multiple Sclerosis Disease ActivityUSPTOApplication 19364861
  • GrantedBiomarkers for Predicting Multiple Sclerosis Disease ActivityUSPTOUS 12,474,336
  • PendingBiomarker Panels for Predicting Multiple Sclerosis Disease ProgressionUSPTOApplication 19190530
Show all 20 patent records
  • Biomarkers for Predicting Multiple Sclerosis Disease ActivityApr 23, 2026 · Application 19364861Pending
  • Biomarkers for Predicting Multiple Sclerosis Disease ActivityNov 18, 2025 · US 12,474,336Granted
  • Biomarker Panels for Predicting Multiple Sclerosis Disease ProgressionNov 13, 2025 · Application 19190530Pending
  • Methods For Assessment Of Multiple Sclerosis ActivityOct 3, 2023 · US 11,773,446Granted
  • 3D Graph Visualizations to Reveal Features of DiseaseSep 14, 2023 · Application 18023813Pending
  • Biomarkers for Predicting Multiple Sclerosis Disease ProgressionAug 24, 2023 · Application 18024149Pending
  • Biomarkers For Predicting Multiple Sclerosis Disease ProgressionApplication PCTUS2021049155Pending
  • 3D Graph Visualizations To Reveal Features Of DiseaseApplication PCTUS2021048442Pending
  • Biomarkers for Predicting Multiple Sclerosis Disease ProgressionApplication 63148906Pending
  • Biomarkers for Predicting Multiple Sclerosis Disease ActivityApplication 63074768Pending
  • Biomarkers For Predicting Multiple Sclerosis Disease ActivityApplication PCTUS2020049375Pending
  • Multivariate Biomarker Panels for Predicting Multiple Sclerosis Disease ActivityApplication 62896430Pending
  • Methods For Assessment Of Multiple Sclerosis ActivityApplication PCTUS2017027810Pending
  • Early Development of a Novel Serum Based Test to Measure Multiple Sclerosis Disease ActivityApplication 62462302Pending
  • Methods and Compositions for Multiple Sclerosis AssessmentApplication 62323541Pending
  • Biomarkers For Predicting Multiple Sclerosis Disease ProgressionApplication PCTUS2023077800Pending
  • Measuring Brain Volumes For Modeling Neurological Disease StateApplication PCTUS2023076710Pending
  • Biomarker Panels for Predicting Multiple Sclerosis Disease ProgressionApplication 63589266Pending
  • Biomarker Panels for Predicting Multiple Sclerosis Disease ProgressionApplication 63419227Pending
  • Measuring Brain Volumes For Modeling Neurological Disease StateApplication 63415528Pending
  • Rad AI, Inc.Similar federal contract value in Medtech · null in contracts
  • Seer BioSimilar federal contract value in Medtech · null in contracts
  • Kardium Inc.Similar federal contract value in Medtech · null in contracts
  • Scilex Holding CoSimilar federal contract value in Medtech · null in contracts
  • Binx HealthSimilar federal contract value in Medtech · null in contracts
  • GENOMIND, INC.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .